Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086489
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2004-07-01
Brief Title:
CP-675206 In Patients With Advanced Melanoma
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Phase 1 Open Label Non-Randomized Dose Escalation Study To Evaluate The Safety Tolerability Pharmacokinetics Immune Function Effects And Efficacy Of Multiple Doses Of CP-675206 In Patients With Advanced Melanoma And Phase 2 Open Label Randomized Study To Evaluate the Efficacy Safety Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675206 In Patients With Advanced Melanoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy safety and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None